Alcoholic Hepatitis Clinical Trial
Official title:
Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis
Alcoholic hepatitis is related to very high mortality rate. About 40% of the patients are
died within first 6 months after the detection of the clinical syndrome. Therefore, it is
very essential for proper diagnosis and early treatment. In response to acute or chronic
liver damage, bone marrow derived stem cells can spontaneously populate liver and
differentiate into hepatic cells. Animal and human studies suggested that injured hepatocyte
may be replaced by pluripotent bone marrow cells. However, this hepatocyte repopulation is
highly dependent on varieties of liver injury and therapeutic conditions. The studies has
suggested Granulocyte-colony stimulating factors (G-CSF) can regenerate hepatocyte by fusing
with hematopoietic cells, thereby enhancing the liver histology and survival rate.
G-CSF is a cytokine capable to regulate a number of functions in neutrophils. In three recent
studies mobilization of bone marrow stem cells induced by G-CSF was observed in patients with
alcoholic hepatitis. In two of this studies there was a survival benefit with the use of
G-CSF.
Therefore we plan to study the safety and efficacy of G-CSF in the patients with alcoholic
hepatitis.
Detailed Description:
Patients with severe alcoholic hepatitis, admitted to Department of Hepatology PGIMER,
Chandigarh will be included in the study.
METHODS
This will be an open label trial. A randomization code is generated by random number table.
The patients will be randomized to receive standard medical therapy (SMT) only as control and
therapy of G-CSF as case. There will be one control and one case as below:
1) SMT (control) 2) G-CSF (case): G-CSF 5 mcg/kg every 12 hourly for consecutive 5 days This
will be a single time therapy. Patients will be admitted in the department of hepatology and
will be assessed everyday clinically as well as by laboratory tests during therapy to assess
safety and effects of treatment.
1. Total leukocytes count will be assessed daily.
2. Circulating CD 34 positive cells will be measured on day 0 and 6 of G-CSF therapy.
3. In addition, ultrasonography will be performed at day 1 and 6 in order to evaluate
difference in spleen size and portal vein flow.
4. Biochemical, coagulation, and hematological parameters (Liver function tests, Renal
Function Tests, Prothrombin Time, International Normalised Ratio, etc.) will be
monitored periodically, daily for 1 week, then weekly for 1month and monthly for three
month.
All patients will be followed at weekly interval for 1 month and then monthly for 3 months.
Outcome:
Primary Objectives:
Survival at 3 months
Secondary Objectives:
Mobilisation of CD34 positive cells in peripheral blood.Clinical/biochemical improvement in
liver function profile.Improvement in prognostic scores-Maddrey's Discriminant function, MELD
score, and Child score.
Safety and efficacy of G-CSF in alcoholic hepatitis
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04066179 -
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
|
N/A | |
Completed |
NCT03732586 -
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00962442 -
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
|
Phase 3 | |
Not yet recruiting |
NCT06307522 -
MRG-001 in Patients With Alcoholic Hepatitis
|
Phase 2 | |
Recruiting |
NCT05018481 -
HA35 Moderate Alcoholic Hepatitis (AH) Study
|
Early Phase 1 | |
Completed |
NCT04544020 -
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
|
||
Recruiting |
NCT04088370 -
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
|
||
Completed |
NCT04235855 -
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
|
N/A | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT00851981 -
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
|
Phase 2 | |
Completed |
NCT04084522 -
Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT05840640 -
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
|
Phase 4 | |
Recruiting |
NCT03069300 -
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
|
Phase 3 | |
Terminated |
NCT02039219 -
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
|
Phase 2 | |
Completed |
NCT02019056 -
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
|
Phase 2 | |
Completed |
NCT01245257 -
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT00388323 -
Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human
|
N/A | |
Recruiting |
NCT03845205 -
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
|
N/A | |
Active, not recruiting |
NCT02473341 -
Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial
|
Phase 3 |